Area:
Aging, Gene Therapy, Vision Research, Cellular Neurobiology
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Jian Wu is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
1994 — 1997 |
Wu, Jian |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Identification of Factors For Nuclear Import of U3 Snrnp |
0.943 |
1997 — 1999 |
Wu, Jian |
F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Development of Liver Specific Liposomes For Therapeutics @ Thomas Jefferson University
Background and aims: This proposal is designed to improve liposome- directed drug delivery and gene therapy for liver disease with the following specific aims: A. To further characterize properties of asialofetuin (AF)-labeled liposomes, such as entrapping efficiency, as well as defining their potential application in drug-delivery and in liver disease; B. To label cationic liposomes, such as Lipofectin (DOTMA/DOPE), DMRlE/DOPE, and Cytofectin (GS2888/DOPE) with asialofetuin, and to study their biodistribution by intravenous or intraportal administration, C. To evaluate gene transfer efficiency by complexes of AF-labeled cationic liposomes-plasmid DNA in hepatoma cell lines, isolated primary hepatocytes and in mouse liver; D. To test transfection efficiency and the therapeutic potential of complexes of AF-labeled liposomes-alpha 1-antitrypsin ribozymes by intraportal or intravenous administration. Methods: A series of different liposomes and liposome-DNA complexes will be generated, and their efficiency will be evaluated by immunohistochemistry of marker proteins, fluorescent staining techniques, Northern and Western blot analysis, as well as the employment of PCR. Significance: The performance and completion of this program will lead to a better understanding of the process of liposome- mediated-gene transfection, and to the development of novel approaches to target the liver, especially hepatocytes. If successfully undertaken, this proposal has the potential of developing new techniques that may positively affect the treatment of a series of different liver conditions, from alcoholic and metabolic liver disease to hepatocellular carcinoma.
|
0.984 |
2005 — 2006 |
Wu, Jian |
R21Activity Code Description: To encourage the development of new research activities in categorical program areas. (Support generally is restricted in level of support and in time.) |
Anti-Oxidative Gene Therapy For Liver Transplantation @ University of California Davis
[unreadable] DESCRIPTION (provided by applicant): Hepatic ischemic/reperfusion (I/R) injury is characterized by the generation of superoxide anions and other superoxide anion-derived reactive oxygen species (ROS), such as, hydrogen peroxide and hydroxyl radicals. To combat these ROS, free radical scavengers, such as superoxide dismutase (SOD) and catalase play crucial roles in the attenuation of hepatic I/R injury. The general goals of this proposal are to evaluate the therapeutic efficacy of extracellular superoxide dismutase (EC-SOD) and/or catalase gene delivery employing non-viral approaches in a mouse model of hepatic I/R injury, and to develop an ex vivo gene delivery approach for small graft liver transplantation. Specific Aims: 1. To deliver the EC-SOD and/or catalase gene with polycationic liposomes in order to prevent subsequent liver damage caused by I/R in mice; 2. To develop an ex vivo technique to deliver the EC-SOD and/or catalase gene to small size liver grafts with polycationic liposomes. Methods: In vivo gene delivery efficiency will be evaluated by determining the expression of EC-SOD and catalase in the liver at the mRNA and protein levels. The protection offered by the gene delivery system will be determined by liver biochemistry and histology. The improvement of graft function will be assessed by animal survival, extent of liver injury, and hepatocyte proliferation. The antioxidative effects of both enzymes will be evaluated by lipid peroxidation in the liver tissue. Health Relatedness: The successful completion of the proposed studies will demonstrate that the delivery of these two anti-oxidative enzyme genes is an effective prophylactic strategy for the improvement of graft function, and that the development of a novel gene delivery approach will improve graft quality and survival. [unreadable] [unreadable] [unreadable]
|
0.984 |